Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.

The document concludes that managing non-classical congenital adrenal hyperplasia in females requires personalized treatment, genetic counseling, and a team of specialists.

The conclusion is that better understanding and more research are needed to effectively manage follicular and scarring disorders in skin of color, with an emphasis on patient education and cultural awareness.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

Hirsute women have lower type 2 17β-HSD enzyme levels, which improve with treatment.

Micro-segmental hair analysis helps detect drug use patterns and estimate drug consumption days.

Daughters of women with PCOS generally experience normal puberty but may have more body hair and different body fat distribution.

The document concludes that lifestyle changes and medical treatments can significantly reduce symptoms of Hidradenitis Suppurativa, a chronic skin condition.

Antiandrogens have important biological effects, but more research is needed to understand them fully and compare their effectiveness and side effects to other treatments.

The document concludes that primary scarring alopecias cause permanent hair loss, have unpredictable outcomes, and lack definitive treatments, requiring personalized care.

The document concludes that diagnosing and treating Congenital Adrenal Hyperplasia is complex and requires a team approach due to its effects on the skin and other symptoms.

Scalp hair grows at 0.37 mm/day, forearm hair at 0.18 mm/day, and thigh hair at 0.30 mm/day, with no significant differences found in people with certain hair conditions.

Testosterone therapy aims to treat hormone deficiencies and various conditions safely and effectively, but requires careful patient monitoring due to potential side effects.

Woman has discoid lupus, frontal fibrosing, and androgenetic alopecia.

Hormonal treatment is effective for women with acne not helped by usual treatments, especially if they have hormonal imbalances.

Women's ovarian hormones and adrenal androgens change throughout life, affecting hair loss and health.

The nafarelin test can reliably distinguish between gonadotropin deficiency and delayed puberty in teenage boys.

Sex hormones affect hair and feather growth and may help manage alopecia and hormone-dependent cancers.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

Finasteride causes lasting fertility decrease in rats.

The document says menstruation is important for women's health, discusses menstrual disorders, and suggests personalized treatment options.

The document concludes that Functional Hypothalamic Amenorrhea should be carefully diagnosed and managed to prevent health complications, using lifestyle changes and specific medications.

Higher androgen levels do not cause baldness in men.

Testosterone replacement therapy should be used for men with low testosterone levels and symptoms of hypogonadism, after careful diagnosis and considering individual needs.

The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.

The gene SDR5A1 is found in scalp hair of both hirsute and normal individuals, but it does not explain differences in hair growth.

Metformin helps manage diabetes, PCOS, and weight in kids but needs more research for long-term safety.

CAH is a genetic disorder affecting cortisol production and causing hormonal imbalances, with treatment and diagnosis varying by form and symptoms.

The severity of symptoms in nonclassical congenital adrenal hyperplasia is not determined by CYP21A2 gene variations.